144
edits
LQTS: Difference between revisions
Jump to navigation
Jump to search
m
no edit summary
mNo edit summary |
mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 145: | Line 145: | ||
450-459 (in males) | 450-459 (in males) | ||
>480 during | >480 during X-ECG | ||
X-ECG | |||
|valign="top"|3 | |valign="top"|3 | ||
| Line 312: | Line 310: | ||
===Medication/Other therapies:=== | ===Medication/Other therapies:=== | ||
*Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolon | *Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolon | ||
==References== | |||
<biblio> | |||
#Schwartz2001 pmid=11136691 | |||
#Alders pmid=20301308 | |||
#adenosine pmid=16105845 | |||
#priori pmid=12736279 | |||
#Adler pmid=22300664 | |||
#Shimizu2009 pmid=19926013 | |||
#Moss pmid=17470695 | |||
#Sy pmid=22042885 | |||
#Schwartz2011 pmid=22083145 | |||
#Viskin pmid=20116193 | |||
#Shimizu2004 pmid=15851169 | |||
</biblio> | |||